

Lower Risks of Incident Colorectal Cancer in SGLT2i Users Compared to DPP4i Users: A Propensity Score-matched Study with Competing Risk Analysis

Running Title: SGLT2i Reduces Risk of Incident Colorectal Cancer

Keywords: Diabetes mellitus; colorectal cancer; SGLT2 inhibitors; DPP4 Inhibitors

Raymond Ngai Chiu Chan ¹, Robert Ngai Fung Chan ¹, Oscar Hou In Chou ¹, Teddy Tai Loy Lee ¹,
Leonardo Roever MHS PhD ², Guoliang Li MD PhD ³, Wing Tak Wong PhD ⁴, Abraham Ka Chung
Wai MBChB FRCP ⁵, Tong Liu MD PhD ⁶, Gary Tse MD PhD FRCP FFPH FRCPATH # ^{1,6,7}, Sharen
Lee MBChB # ¹

¹ Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

² Department of Clinical Research, Federal University of Uberlandia, Uberlândia, Brazil

³ Department of Cardiology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an,
China

⁴ School of Life Sciences, Chinese University of Hong Kong, Hong Kong, China

⁵ Department of Emergency Medicine, School of Clinical Medicine, University of Hong Kong,
Hong Kong, China

⁶ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of
Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University,
Tianjin 300211, China

⁷ Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, UK

Correspondence to:

Gary Tse, MD PhD FRCP FFPH FRCPATH

Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, UK

Email: gary.tse@kmms.ac.uk

Tel: +44 7309321109

Sharen Lee, MBChB

Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China-UK Collaboration

Email: sharen212@gmail.com

Contribution of Authors

RNCC and RNFC are responsible for study concept and design, analysis and interpretation of data, drafting the manuscript, and statistical analysis. OHIC is responsible for study concept and design, as well as acquisition of data. TTLL, LR, GL, WTW, AKCW, TL are responsible for study concept and design, as well as critical revision of the manuscript for important intellectual content. GT and SL are responsible for study concept and design, critical revision of the manuscript for important intellectual content, and study supervision.

Conflict of Interest

None.

Financial Support

None.

50 **Abstract**

51 **Background:** Diabetes mellitus is associated with the development of colorectal cancer (CRC).

52 There have been a lack of study comparing the risk of colorectal cancer in sodium-glucose co-
53 transporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP4i), both of which
54 commonly prescribed second line agents for diabetes.

55 **Methods:** We conducted a territory wide retrospective cohort study on patients with type 2 diabetes
56 who was prescribed either of the two agents. Baseline demographics, use of other medications,
57 comorbidities and biochemical parameters were extracted. Propensity score matching was performed
58 to reduce the impacts of cofounders. Cause specific Cox regression was used to evaluate the risk of
59 incident colorectal cancer in SGLT2i users, as compared to DPP4i users. Subgroup analyses based
60 on age, gender and estimated glomerular filtration rate were performed.

61 **Results:** After propensity score matching, we included 13029 subjects who were prescribed SGLT2i
62 and DPP4i respectively. Incidence rate ratio of CRC was 0.566 (0.418-0.766) in SGLT2i users.
63 Overall, use of SGLT2i was associated with a lower risk of incident CRC (HR: 0.526; 95% CI:
64 0.382-0.724; P <0.001). In subgroup analyses, use of SGLT2i was associated with lower risks of
65 incident CRC only in men (HR: 0.461; 95% CI: 0.303-0.702; P <0.001), patients < 65 years old and
66 patients (HR:0.294; 95% CI: 0.174-0.496; P<0.001) with eGFR ≥ 45 mL/min/ 1.73m² (HR: 0.560;
67 95% CI: 0.395-0.792; P =0.001).

68 **Conclusion:** Use of SGLT2i may reduce risk of incident CRC as compared to use of DPP4i,
69 especially in younger male patients with fairly preserved renal function.

70

INTRODUCTION

Diabetes mellitus is a global public health issue affecting 536.6 million people worldwide in 2021¹. Previous studies have established clear epidemiological links between diabetes mellitus and various co-morbidities, including malignancies like liver, pancreatic, endometrial and colorectal cancers (CRC)^{2,3}. A meta-analysis in 2013, which pooled data from 20 controlled trials and cohort studies after 2007, reported a higher risk of incident CRC as well as a higher CRC-specific mortality in diabetic patients⁴. Several groups have investigated the effects of anti-diabetic medications on the risk of CRC. Metformin, an oral anti-hyperglycemic agent recommended by the American Diabetes Association as the preferred initial pharmacologic treatment for type 2 diabetes mellitus (T2DM), was found to have a protective effect on incident CRC by several studies⁵⁻⁷, although conflicting results have been generated by other groups⁸⁻¹¹. The effects of newer anti-diabetic medications, especially dipeptidyl peptidase 4 inhibitors (DPP4i) and sodium-glucose co-transporter 2 inhibitors (SGLT2i), were less studied.

DPP4i and SGLT2i are two emerging drug classes approved by the FDA for the treatment of T2DM¹². Given the protective effects of DPP4i on pancreatic beta cells function, as well as the cardioprotective and renoprotective effects of SGLT2i, both are increasingly prescribed as second line treatment for T2DM¹³⁻¹⁶. Preclinical studies on DPP4i and SGLT2i have highlighted their potentials in CRC suppression¹⁷⁻¹⁹. Although there are few studies evaluating the effects of DPP4i on CRC, most of them were of small scale and none directly compared it with SGLT2i²⁰. Whether any of these agents could alter the risk of incident CRC in T2DM patients remains unclear. Hence in the present study, we aim to compare the risk of incident CRC in DPP4i and SGLT2i users amongst T2DM patients using a large territory wide cohort in Hong Kong.

METHODS

Study design and population

This was a territory-wide retrospective cohort study in T2DM patients treated with SGLT2i or DPP4i between January 1st, 2016, and December 31st, 2019 in Hong Kong. Patients were followed up until December 31st, 2020, or death, whichever came earlier. The current study was approved by The Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee. Subjects were identified from the Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority in Hong Kong. It is a territory-wide database that centralizes patient information from all public hospitals and clinics in Hong Kong, which facilitates retrieval of clinical characteristics, disease diagnosis, laboratory results and drug treatment details. It has been used by local teams in Hong Kong to conduct studies on T2DM²¹⁻²³, and recently by our team comparing the cardiovascular outcomes between SGLT2I and DPP4I users²⁴⁻²⁶.

Patients were excluded if any of the following criteria were met: 1) less than one year of drug exposure; 2) on both DPP4I and SGLT2I, or switched between the two drug classes; 3) died within 30 days after initial drug exposure; 4) less than 18 years old at the start of the study; 5) pregnancy; 6) without complete demographics 7) with no HbA1c records at baseline; 8) with a history of colorectal cancer prior to baseline.

Patients' demographics, clinical and biochemical data were extracted for the present study. Comorbidities at baseline were defined and extracted using the International Classification of Diseases Ninth Edition (ICD-9) codes (**Supplementary Table 1**). Charlson's standard comorbidity index was calculated. Use of anti-diabetic and lipid-lowering agents were extracted. Baseline biochemistry, including the complete blood count, renal function tests, liver function tests, lipid and glycemic profiles were extracted. Estimated glomerular filtration rate (eGFR) was calculated by the abbreviated modification of diet in renal disease (MDRD) formula²⁷.

Adverse outcomes and statistical analysis

The primary endpoint of the present study was incident colorectal cancer (ICD-9: 153-154).

Mortality data were obtained from the Hong Kong Death Registry, a population-based official government registry with the registered death records of all Hong Kong citizens linked to CDARS. The endpoint date of interest for eligible patients was the event presentation date. The endpoint for those without primary outcome presentation was the mortality date or the endpoint of the study (December 31st, 2020).

For baseline clinical characteristics, continuous and categorical variables were presented as mean (standard deviation [SD]) and frequency (percentage) respectively. Propensity score matching (PSM) with a 1:1 ratio for SGLT2i users versus DPP4i users based on age, gender, Charlson's comorbidity index, other comorbidities and non-SGLT2i/ DPP4i medications was performed using the nearest neighbor search strategy. Baseline characteristics between patients with SGLT2i and DPP4i use before and after matching were compared with standardized mean difference (SMD), with SMD<0.20 regarded as well-balanced. The incidence of new-onset colorectal cancer was derived from dividing the number of outcomes by person-year at risks, which estimate the number of years at risks. Cause specific hazard models were used to calculate the unadjusted and adjusted hazard ratios. Important covariates were adjusted by backward selection. HDL was considered as a surrogate marker of BMI and was adjusted in addition to other covariates. It has been shown to correlate better with BMI as compared to other serum lipids²⁸⁻³¹. Fine Gray's subdistribution hazard models were conducted as sensitivity analyses. Subgroup analyses were performed in patients ≥ 65 years old, < 65 years old, male and female. We aimed to evaluate the impact of renal function on the effects of SGLT2i and/or DPP4i, hence subgroup analyses were also performed in patients with eGFR ≥ 45 mL/min/ 1.73m² and <45 mL/min/ 1.73m² respectively. The hazard ratios (HR), 95% CI and P-value were reported. Statistical significance was taken as P-value < 0.05 . All statistical analyses were performed with RStudio software (Version: 1.1.456).

RESULTS

Baseline characteristics of the study population

In this retrospective cohort study, 86 353 patients in Hong Kong using SGLT2i/DPP4i between January 1st, 2016 and December 31st, 2019 were recruited. They were followed up until December 31st, 2020 or deaths, which ever came earlier. Patients with less than one month of drug exposure (n = 3019), on both DPP4i and SGLT2i (n = 13529), died within 30 days after initial drug exposure (n = 4491), less than 18 years old at baseline (n = 592), less than 1 year of drug exposure (n = 1781), pregnancy (n = 19), without complete demographics or mortality data (n = 15), without baseline HbA1c (n = 9766), with CRC prior to baseline (n = 289) were excluded.

Subsequently, 18 741 SGLT2i users and 33 839 DPP4i users were included. After 1:1 propensity score matching, 13 029 patients on SGLT2i and DPP4i respectively entered statistical analyses. In the matched cohort, 65 (0.5%) SGLT2i users and 118 (0.9%) DPP4i users developed incident CRC. The baseline characteristic of patients before and after PSM are shown in **Supplementary Table 2 and Table 1** respectively.

SGLT2i use is associated with reduced risk of incident CRC

Over a follow-up period of 117734.1 person-years, 183 incident CRC were identified. Overall, the incidence of CRC (IRR: 0.566; 95% CI: 0.418-0.766; P<0.001) were lower amongst SGLT2i users compared to DPP4i users after PSM (**Table 2**). We used univariable Cox regression to identify the potential risk factors of incident CRC before and after PSM, which were serially adjusted in subsequent multivariable models (**Supplementary Table 3 and 4**). Unadjusted and adjusted hazard ratios for incident CRC were presented in **Table 3**. In all models, use of SGLT2i was significantly associated with lower risks of incident CRC as compared to use of DPP4i. After adjusting for age, gender, HbA1c, use of other medications, comorbidities and HDL, use of SGLT2i was associated with an approximately 47.4% reduction in the risk of incident CRC (HR: 0.526; 95% CI: 0.382-0.724; P<0.001).

Sensitivity analyses were performed using Fine-Gray's subdistribution regression model to confirm the predictiveness of the models. Similarly, use of SGLT2i was associated with lower risks of incident CRC in the sensitivity analyses after serial adjustment of important covariates identified in univariable analyses (**Supplementary Table 5**). In model 5, use of SGLT2i was associated with a 42.5% reduction in risk of incident CRC (HR: 0.575; 95% CI: 0.368-0.896; P= 0.015).

Effects of SGLT2i on the risk of incident CRC stratified by age and gender

Sub-group analyses based on age and gender were further performed. In male, use of SGLT2i was associated with lower risks of incident CRC (HR: 0.461; 95% CI: 0.303-0.702; P <0.001) but no significant association was found in female (**Table 4**). Similar results were reproduced in the sensitivity analyses using Fine-Gray's subdistribution hazard models (HR: 0.505; 95% CI: 0.339-0.752; P <0.001) (**Supplementary Table 6**). In patients younger than 65 years old, use of SGLT2i was associated with reduced risks of incident CRC (HR: 0.294; 95% CI: 0.174-0.496; P <0.001) whereas no significant association was found in the older group (**Table 5**). Again, similar results were observed in sensitivity analyses (HR: 0.328; 95% CI: 0.198-0.546; P<0.001). (**Supplementary Table 7**)

Effects of SGLT2i on the risk of incident CRC stratified by eGFR

To assess the impact of eGFR on the effects of SGLT2i, we conducted subgroup analyses based on the eGFR. As the number of incident CRC in patients with eGFR < 45 mL/min/ 1.73m² is inadequate to perform a robust analysis, the unmatched cohort were used. In patients with eGFR ≥ 45 mL/min/ 1.73m², use of SGLT2i was correlated with a significantly reduced risk of incident CRC (HR: 0.560; 95% CI: 0.395-0.792; P = 0.001). However, in patients with more advanced CKD, the association was lost. (**Table 6**) Sensitivity analyses yielded similar findings (**Supplementary Table 8**).

196

197 *SGLT2i use is associated with lower all-cause mortality in patients who developed incident CRC*

198 We compared the all-cause mortality of patients with incident CRC amongst SGLT2i and DPP4i
199 users. Given the limited number of deaths with incident CRC in the matched cohort, the analyses
200 were, again, performed in the unmatched cohort. Use of SGLT2i was not associated with lower risks
201 of all-cause mortality (HR: 0.285; 95% CI: 0.066-1.25; P = 0.097) after adjusted for age, gender
202 HbA1c, use of medications, and comorbidities (**Supplementary Table 9**).

203

204 **DISCUSSION**

205 In the present study, we used a territory-wide cohort to compare the risk of incident CRC
206 amongst SGLT2i and DPP4i users. To our knowledge, this is the first study thus far to evaluate the
207 incidence of CRC amongst patients treated with the named medications. Importantly, we were able
208 to demonstrate several clinically relevant findings: 1) use of SGLT2i was associated with a lower
209 risk of incident CRC after serial adjustment. 2) The effects of SGLT2i on incident CRC, as compared
210 to DPP4i, differ with respect to patients' age, gender and renal function. 3) Use of SGLT2i may not
211 reduce all-cause mortality in DM patients with incident CRC. These findings are of clinical
212 significance as SGLT2i and DPP4i are both commonly prescribed second line pharmacological
213 treatment for T2DM.

214

215 *SGLT2i Reduce Risk of Incident CRC via an eGFR-Dependent Pathway*

216 Diabetes mellitus and insulin resistance have been recognized to be major risk factors of
217 various malignancies including CRC, although the exact mechanism remains unclear^{2, 3}.
218 Hyperinsulinemia, which characterizes pre-diabetes and early diabetes, was known to promote
219 cancer cell survival and mitogenesis via binding to insulin and insulin-like growth factor (IGF)
220 receptors that are widely expressed on cancer cells membrane³²⁻³⁴. Other mechanisms, such as

upregulation of inflammatory cytokines, alterations of cellular energetics and shared risk factors, have previously been proposed^{2, 35}. In view of the epidemiological and biological links between CRC and diabetes mellitus, studies have investigated the relationship between different anti-diabetic medications and incident CRC.

Currently, there is a lack of evidence on the effects of SGLT2i, a relatively new agent for T2DM that inhibits SGLT2 in the kidney to promote glycosuria, on incident CRC³⁶. In contrary to most anti-diabetic medications, its major mechanism of action is independent of insulin. Studies suggested that use of SGLT2i improved insulin sensitivity and potentially lowers plasma insulin level^{37, 38}. Preclinical animal models echoed this finding by showing a dramatically reduced plasma insulin in SGLT2 knockout mice³⁹. Furthermore, use of SGLT2i has been shown to improve shared risk factors between CRC and diabetes, reduce circulating inflammatory cytokines, attenuate vascular endothelial and smooth muscle cells proliferation in response to interleukins, alter cellular energetics and suppress oxidative stress, all of which may be protective factors against malignancies such as CRC^{37, 40-42}. However, whether SGLT2i reduces risk of incident CRC and the actual mechanisms, if any, remain unknown.

In the present study, we demonstrated that SGLT2i significantly reduced the risk of incident CRC, and the association was only significant when the eGFR was ≥ 45 mL/min/ 1.73m². Apparently, the glycosuria effects of SGLT2i depends on relatively preserved glomerular function. A previous study suggested that the glucose lowering effect of SGLT2i was attenuated when the eGFR dropped to < 45 mL/min/ 1.73m², while another suggested that the effect was lost when the eGFR dropped to < 30 mL/min/ 1.73m²^{43, 44}. In our study, we were able to demonstrate that the protective effect of SGLT2i against incident CRC, as compared to DPP4i, was independent of glycemic control by adjusting for HbA1c, but the association was lost when the eGFR was below 45 mL/min/ 1.73m². Hence, it is reasonable to hypothesize that SGLT2i may reduce the risk of incident CRC via its glycosuria effect, which reduces circulating insulin level at any given blood glucose level and

downregulates farnesylated Ras protein to suppress mitogenesis⁴⁵. Although the role of chronic inflammation and SGLT2 expression on CRC cell lines has been previously implicated, a recent study showed that oral administration of SGLT2i in obese and diabetic mice with azoxymethane-induced colorectal pre-neoplastic lesions appeared to reduce IGF-1 and several related signaling molecules in the colonic mucosa, while direct administration of SGLT2i on human CRC cell lines exhibited no impacts on cellular proliferation, further supporting our hypothesis⁴⁶. Further investigations are warranted to validate these findings.

Differential effects of SGLT2i across gender and age

In the present study, we also demonstrated that SGLT2i only reduced risk of incident CRC in male and younger patients, but not their female or older counterparts. In fact, gender dimorphism in CRC in terms of the incidence, molecular pathogenesis and prognosis have been previously reported^{47, 48}. Lifestyle factors, hormonal differences, and more recently single nucleotide polymorphisms or genetic variants have been proposed to explain these differences⁴⁹⁻⁵².

Several epidemiological studies have suggested that the relationship between obesity and CRC is stronger in male than female, potentially due to the fact the protective effect of estrogen over insulin resistance and subsequent hyperinsulinemia⁵³⁻⁵⁷. Recent studies also suggested the insulin-IGF axis is preferentially upregulated in men with CRC^{58, 59}. Differences in the level and biological action of insulin and IGF across the two genders may potentially account for the discrepancy. Meanwhile, elderly patients with T2DM may have relatively less preserved pancreatic β -cell function and renal function while insulin sensitivity appeared to be similar in older and younger subjects with comparable BMI⁶⁰⁻⁶². These may limit the effects of SGLT2i on preventing incident CRC.

Strengths and limitations

With the use of medical records from a territory-wide database, CDARS, our study was able to detect relatively rare outcomes, such as incident CRC, with an adequate sample size and follow-up duration. The present study was also the first to compare the difference in CRC incidence amongst T2DM patients treated with SGLT2i and DPP4i. Subgroup analyses in our study may also provide mechanistic insight into the anti-tumour effects of SGLT2i. However, there are still certain limitation in our study. First, although CDARS has been considered a relatively reliable source of clinical data, there was unavoidably information bias due to the risk of under-coding, coding errors and missing data. Second, BMI has been considered an important risk factor of CRC but was not available in our database. The use of HDL as a surrogate marker may potentially and partially adjust for this limitation. Third, the retrospective nature of our study did not allow measurement of drug concentration, which might correlate with the outcomes. Fourth, the present study aimed at assessing the epidemiological links between use of SGLT2i and DPP4i with incident CRC and could not address the causal or mechanistic relationship. Lastly, SGLT2I and DPP4I are drug classes constituting a variety of agents from different brands with their respective formula. The present study did not conduct further analyses to compare the effects of different agents in the same drug class.

CONCLUSION

SGLT2i use is associated with a reduced risk of incident CRC compared to DPP4i use. The association was significant only in younger patients, male and in patients with an eGFR ≥ 45 mL/min/ 1.73m². SGLT2i use was not associated with a lower all-cause mortality in diabetic patients with incident CRC. Further studies are warranted to validate the findings.

ACKNOWLEDGEMENTS

Nil

CONFLICT OF INTEREST

Nil

FUNDING

Nil

REFERENCES

1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* 2022;183:109119.
2. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and Cancer: A consensus report. *Diabetes Care* 2010;33:1674-1685.
3. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. *Endocr Relat Cancer* 2009;16:1103-23.
4. De Bruijn KM, Arends LR, Hansen BE, et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. *Br J Surg* 2013;100:1421-9.
5. Sehdev A, Shih YC, Vekhter B, et al. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. *Cancer* 2015;121:1071-8.
6. Chang YT, Tsai HL, Kung YT, et al. Dose-Dependent Relationship Between Metformin and Colorectal Cancer Occurrence Among Patients with Type 2 Diabetes- A Nationwide Cohort Study. *Transl Oncol* 2018;11:535-541.
7. Rennert G, Rennert HS, Gronich N, et al. Use of metformin and risk of breast and colorectal cancer. *Diabetes Res Clin Pract* 2020;165:108232.
8. Spillane S, Bennett K, Sharp L, et al. Metformin exposure and disseminated disease in patients with colorectal cancer. *Cancer Epidemiology* 2014;38:79-84.
9. Shin CM, Kim N, Han K, et al. Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study. *Cancer Epidemiology* 2020;64:101658.
10. Cardel M, Jensen SM, Pottegard A, et al. Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. *Cancer Med* 2014;3:1458-66.
11. Lin CM, Huang HL, Chu FY, et al. Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. *PLoS One* 2015;10:e0125421.
12. Ferro EG, Michos ED, Bhatt DL, et al. New Decade, New FDA Guidance for Diabetes Drug Development. *Journal of the American College of Cardiology* 2020;76:2522-2526.
13. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. *Nat Rev Endocrinol* 2020;16:642-653.

14. Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. *Circulation* 2017;136:1643-1658.
15. Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. *Circulation* 2016;134:752-72.
16. Alicic RZ, Johnson EJ, Tuttle KR. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. *Am J Kidney Dis* 2018;72:267-277.
17. Nasiri AR, Rodrigues MR, Li Z, et al. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. *Cancer & Metabolism* 2019;7:10.
18. Kato J, Shirakami Y, Ohnishi M, et al. Suppressing effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice. *Oncol Rep* 2019;42:2797-2805.
19. Amritha CA, Kumaravelu P, Chellathai DD. Evaluation of Anti Cancer Effects of DPP-4 Inhibitors in Colon Cancer- An Invitro Study. *J Clin Diagn Res* 2015;9:Fc14-6.
20. Overbeek JA, Bakker M, van der Heijden A, et al. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. *Diabetes Metab Res Rev* 2018;34:e3004.
21. Lee S, Liu T, Zhou J, et al. Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study. *Acta Diabetol* 2021;58:171-180.
22. Lee S, Zhou J, Guo CL, et al. Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death. *Endocrinol Diabetes Metab* 2021;4:e00240.
23. Lee S, Jeevaratnam K, Liu T, et al. Risk stratification of cardiac arrhythmias and sudden cardiac death in type 2 diabetes mellitus patients receiving insulin therapy: A population-based cohort study. *Clin Cardiol* 2021;44:1602-1612.
24. Lee S, Zhou J, Leung KSK, et al. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong. *Cardiovasc Drugs Ther* 2022.
25. Zhou J, Lee S, Leung KSK, et al. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. *ESC Heart Fail* 2022;9:1388-1399.
26. Mui JV, Zhou J, Lee S, et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis. *Front Cardiovasc Med* 2021;8:747620.
27. Soliman AR, Fathy A, Khashab S, et al. Comparison of abbreviated modification of diet in renal disease formula (aMDRD) and the Cockcroft-Gault adjusted for body surface (aCG) equations in stable renal transplant patients and living kidney donors. *Ren Fail* 2013;35:94-7.
28. Erem C, Hacihasanoglu A, Deger O, et al. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. *Endocrine* 2008;34:36-51.
29. Stepien A, Stepien M, Wlazel RN, et al. Assessment of the relationship between lipid parameters and obesity indices in non-diabetic obese patients: a preliminary report. *Med Sci Monit* 2014;20:2683-8.
30. Boyd GS, Koenigsberg J, Falkner B, et al. Effect of obesity and high blood pressure on plasma lipid levels in children and adolescents. *Pediatrics* 2005;116:442-6.

31. Kucukhuseyin O, Kurnaz O, Akadam-Teker AB, et al. The association of MTHFR C677T gene variants and lipid profiles or body mass index in patients with diabetic and nondiabetic coronary heart disease. *J Clin Lab Anal* 2013;27:427-34.
32. Zhang H, Pelzer AM, Kiang DT, et al. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. *Cancer Res* 2007;67:391-7.
33. Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. *Cell Commun Signal* 2009;7:14.
34. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. *J Nutr* 2001;131:3109S-20S.
35. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 2009;324:1029-33.
36. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. *Curr Opin Endocrinol Diabetes Obes* 2017;24:73-79.
37. Xu L, Nagata N, Nagashimada M, et al. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. *EBioMedicine* 2017;20:137-149.
38. Yaribeygi H, Sathyapalan T, Maleki M, et al. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. *Life Sci* 2020;240:117090.
39. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. *Diabetes* 2011;60:890-8.
40. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. *Diabetes Metab* 2018;44:457-464.
41. Sukhanov S, Higashi Y, Yoshida T, et al. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1beta and IL-18 secretion. *Cell Signal* 2021;77:109825.
42. Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. *Sci Rep* 2018;8:5276.
43. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. *Kidney Int* 2014;85:962-71.
44. Cherney DZI, Cooper ME, Tikkanen I, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. *Kidney Int* 2018;93:231-244.
45. Draznin B. Mechanism of the mitogenic influence of hyperinsulinemia. *Diabetol Metab Syndr* 2011;3:10.
46. Kato J, Shirakami Y, Ohnishi M, et al. Suppressing effects of the sodiumglucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice. *Oncol Rep* 2019;42:2797-2805.
47. Yang Y, Wang G, He J, et al. Gender differences in colorectal cancer survival: A meta-analysis. *Int J Cancer* 2017;141:1942-1949.

48. White A, Ironmonger L, Steele RJC, et al. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. *BMC Cancer* 2018;18:906.
49. Tan SC, Suzairi MS, Aizat AA, et al. Gender-specific association of NFKBIA promoter polymorphisms with the risk of sporadic colorectal cancer. *Med Oncol* 2013;30:693.
50. Martinelli M, Scapoli L, Cura F, et al. Colorectal cancer susceptibility: apparent gender-related modulation by ABCB1 gene polymorphisms. *J Biomed Sci* 2014;21:89.
51. Conti L, Del Corno M, Gessani S. Revisiting the impact of lifestyle on colorectal cancer risk in a gender perspective. *Crit Rev Oncol Hematol* 2020;145:102834.
52. Nussler NC, Reinbacher K, Shanny N, et al. Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. *Gend Med* 2008;5:209-17.
53. West DW, Slaterry ML, Robison LM, et al. Dietary intake and colon cancer: sex- and anatomic site-specific associations. *Am J Epidemiol* 1989;130:883-94.
54. Mao Y, Pan S, Wen SW, et al. Physical inactivity, energy intake, obesity and the risk of rectal cancer in Canada. *Int J Cancer* 2003;105:831-7.
55. Slaterry ML, Caan BJ, Potter JD, et al. Dietary energy sources and colon cancer risk. *Am J Epidemiol* 1997;145:199-210.
56. Morimoto LM, Newcomb PA, White E, et al. Insulin-like growth factor polymorphisms and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* 2005;14:1204-11.
57. De Paoli M, Zakharia A, Werstuck GH. The Role of Estrogen in Insulin Resistance: A Review of Clinical and Preclinical Data. *Am J Pathol* 2021;191:1490-1498.
58. Zeljkovic A, Mihajlovic M, Stefanovic A, et al. Potential use of serum insulin-like growth factor 1 and E-cadherin as biomarkers of colorectal cancer. *Colorectal Dis* 2020;22:2078-2086.
59. Yamaji T, Iwasaki M, Sasazuki S, et al. Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia. *Int J Obes (Lond)* 2012;36:440-7.
60. Bellary S, Kyrou I, Brown JE, et al. Type 2 diabetes mellitus in older adults: clinical considerations and management. *Nat Rev Endocrinol* 2021;17:534-548.
61. Amati F, Dube JJ, Coen PM, et al. Physical inactivity and obesity underlie the insulin resistance of aging. *Diabetes Care* 2009;32:1547-9.
62. Karakelides H, Irving BA, Short KR, et al. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. *Diabetes* 2010;59:89-97.




Figure 1: Flow Diagram for Subjects Selection and Propensity Score Matching

Characteristics	SGLT2I Users	DPP4I Users	SMD
Demographic			
Male	7350 (56.4)	7122 (54.7)	0.035
Age	60.4 (10.8)	61.2 (11.2)	0.073
Follow-up Duration	1810 (104)	1770 (205)	
Charlson's Score	1.81 (1.26)	1.87 (1.33)	0.043
Microvascular Complications			
Diabetic Retinopathy	795 (6.10)	693 (5.32)	0.034
Diabetic Nephropathy	8454 (64.9)	8497 (65.2)	0.007
Diabetic Neuropathy	212 (1.63)	181 (1.39)	0.020
Macrovascular Complications			
Heart Failure	396 (3.04)	294 (2.26)	0.049
Acute Myocardial Infarct	398 (3.05)	331 (2.54)	0.031
Stroke/ Transient Ischemic Attack	402 (3.09)	394 (3.02)	0.004
Atrial Fibrillation	394 (3.02)	243 (1.87)	0.075
Other Comorbidities			
Hyperlipidemia	416 (3.19)	332 (2.55)	0.039
Hypertension	3242 (24.9)	2947 (22.6)	0.053
Immune Mediated Enterocolitis	714 (5.48)	617 (4.74)	0.034
Other Cancer	286 (2.20)	308 (2.36)	0.011
Anti-Diabetic and Lipid-Lowering Medications			
Metformin	12133 (93.1)	12202 (93.7)	0.021
Sulphonylurea	10282 (78.9)	10649 (81.7)	0.071
Insulin	6240 (47.9)	5645 (43.3)	0.092
Acarbose	374 (2.87)	342 (2.62)	0.015
Thiazolidinedione	2843 (21.8)	2470 (19.0)	0.071
Glucagon-Like-Peptide Agonist	240 (1.84)	146 (1.12)	0.060
Statins	9915 (76.1)	9636 (74.0)	0.049
Complete Blood Count			
Red Cell Count	4.70 (0.58)	4.52 (0.689)	0.276
Mean Corpuscular Volume	87.0 (7.25)	87.0 (7.77)	0.005
Mean Corpuscular Hemoglobin Concentration	29.3 (2.89)	29.4 (3.13)	0.049
White Cell Count	7.89 (2.55)	8.07 (2.92)	0.066
Neutrophil	5.06 (2.35)	5.42 (2.92)	0.135
Lymphocyte	2.13 (0.956)	1.97 (0.802)	0.179
Neutrophil to Lymphocyte Ratio	2.97 (3.63)	3.68 (4.82)	0.164
Eosinophil	0.212 (0.185)	0.211 (0.217)	0.008
Platelet	242 (67.7)	243 (72.6)	0.012
Platelet to Lymphocyte Ratio	134 (176)	148 (144)	0.089
Renal Function Test			
Sodium	139.2 (2.75)	139.2 (2.90)	<0.001
Potassium	4.31 (0.44)	4.34 (0.481)	0.055
Urea	5.72 (1.96)	6.34 (3.53)	0.216
Creatinine	78.7 (28.3)	92.9 (87.9)	0.217
Estimated Glomerular Filtration Rate	83.4 (22.2)	78.6 (26.5)	0.196
Liver Function Test			
Alkaline Phosphatase	74.2 (26.8)	78.1 (33.4)	0.126
Aspartate Transaminase	28.0 (29.0)	27.8 (34.8)	0.007
Alanine Transaminase	31.5 (29.9)	29.3 (31.8)	0.073
Bilirubin	11.6 (6.27)	11.4 (6.21)	0.028
Protein	74.4 (4.95)	73.5 (5.54)	0.165
Albumin	42.5 (3.28)	41.6 (4.08)	0.230
Lipid Profile			
Triglyceride	1.72 (1.64)	1.68 (1.40)	0.026
Total Cholesterol	4.31 (0.990)	4.39 (0.971)	0.080
High-Density Lipoprotein	1.18 (0.315)	1.20 (0.326)	0.079
Low-Density Lipoprotein	2.38 (0.790)	2.44 (0.800)	0.084
Glucose Control			
Glycated Hemoglobin	8.06 (1.72)	8.06 (1.71)	0.003
Fasting Blood Glucose	9.02 (3.52)	8.99 (4.15)	0.007

Outcomes			
Death	346 (2.66)	1062 (8.15)	
Incident CRC	65 (0.499)	118 (0.906)	

Table 1: Baseline Demographics of SGLT2i and DPP4i Users after Propensity Score Matching

	Person-Years	Number of Event	IR [95% CI]	IRR [95% CI]
Before Propensity Score Matching				
Overall	252767	471	1.86 [1.70-2.04]	-
DPP4i Users	159796.7	377	2.36 [2.13-2.61]	-
SGLT2i Users	92970.32	94	1.01 [0.817-1.24]	0.429 [0.342-0.537]
After Propensity Score Matching				
Overall	117734.1	183	1.55 [1.34- 1.80]	-
DPP4i Users	58083.66	118	2.03 [1.68-2.43]	-
SGLT2i Users	59650.41	65	1.09 [0.841-1.39]	0.566 [0.418-0.766]

Table 2: Annualized Incidence Rate of CRC per 1000 Person-Year before and after Propensity Score Matching.

	Hazard ratios	95% CI	P-value
Before Propensity Score Matching			
Model 1	0.424	0.338-0.531	<0.001
Model 2	0.599	0.474-0.760	<0.001
Model 3	0.599	0.474-0.759	<0.001
Model 4	0.579	0.444-0.758	<0.001
Model 5	0.588	0.449-0.769	<0.001
Model 6	0.572	0.431-0.759	0.001
After Propensity Score Matching			
Model 1	0.531	0.392-0.719	<0.001
Model 2	0.548	0.405-0.742	<0.001
Model 3	0.548	0.405-0.742	<0.001
Model 4	0.537	0.397-0.728	<0.001
Model 5	0.535	0.395-0.725	<0.001
Model 6	0.526	0.382-0.724	<0.001

Table 3: Univariable and Multivariable Cause-Specific Cox Regression after Propensity Score Matching

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age and gender. Model 3: Adjusted for age, gender and HbA1c. Model 4: Adjusted for age, gender, HbA1c and use of other medications. Model 5: Adjusted for age, gender, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, gender, HbA1c, use of medications, comorbidities, and HDL.

	Hazard ratios	95% CI	P-value
Male			
Model 1	0.467	0.314-0.692	<0.001
Model 2	0.481	0.324-0.714	<0.001
Model 3	0.480	0.323-0.713	<0.001
Model 4	0.481	0.324-0.715	<0.001
Model 5	0.478	0.322-0.710	<0.001
Model 6	0.461	0.303-0.702	<0.001
Female			
Model 1	0.639	0.398-1.03	0.064
Model 2	0.481	0.324-0.714	0.097
Model 3	0.670	0.417-1.08	0.098
Model 4	0.624	0.388-1.01	0.053
Model 5	0.624	0.387-1.01	0.053
Model 6	0.616	0.374-1.01	0.056

Table 4: Univariable and Multivariable Cause-Specific Cox Regression after Propensity Score Matching in Patient Subgroup Stratified by Gender

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age. Model 3: Adjusted for age and HbA1c. Model 4: Adjusted for age, HbA1c and use of other medications. Model 5: Adjusted for age, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, HbA1c, use of other medications, comorbidities and HDL.

	Hazard ratios	95% CI	P-value
Subjects < 65 Years Old			
Model 1	0.347	0.210-0.692	<0.001
Model 2	0.341	0.206-0.562	<0.001
Model 3	0.341	0.207-0.562	<0.001
Model 4	0.321	0.194-0.530	<0.001
Model 5	0.321	0.195-0.531	<0.001
Model 6	0.294	0.174-0.496	<0.001
Subject ≥ 65 Years Old			
Model 1	0.727	0.493-1.07	0.107
Model 2	0.738	0.501-1.09	0.126
Model 3	0.737	0.500-1.09	0.124
Model 4	0.735	0.498-1.09	0.122
Model 5	0.722	0.489-1.07	0.102
Model 6	0.767	0.505-1.16	0.211

Table 5: Univariable and Multivariable Cause-Specific Cox Regression after Propensity Score Matching in Patient Subgroup Stratified by Age

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age and gender. Model 3: Adjusted for age, gender and HbA1c. Model 4: Adjusted for age, gender, HbA1c and use of other medications. Model 5: Adjusted for age, gender, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, gender, HbA1c, use of other medications, comorbidities and HDL.

	Hazard ratios	95% CI	P-value
eGFR ≥ 45mL/min/ 1.73m²			
Model 1	0.474	0.359-0.624	<0.001
Model 2	0.605	0.454-0.807	<0.001
Model 3	0.605	0.454-0.807	<0.001
Model 4	0.570	0.409-0.795	<0.001
Model 5	0.580	0.416-0.809	0.001
Model 6	0.560	0.395-0.792	0.001
eGFR < 45mL/min/ 1.73m²			
Model 1	0.480	0.177-1.31	0.151
Model 2	0.549	0.201-1.50	0.243
Model 3	0.551	0.202-1.51	0.245
Model 4	0.472	0.158-1.41	0.178
Model 5	0.480	0.161-1.44	0.189
Model 6	0.524	0.173-1.59	0.253

Table 6: Univariable and Multivariable Cause-Specific Cox Regression before Propensity Score Matching in Patient Subgroup Stratified by eGFR

Model 1: Unadjusted hazard ratio. Model 2: Adjusted for age and gender. Model 3: Adjusted for age, gender and HbA1c. Model 4: Adjusted for age, gender, HbA1c and use of other medications. Model 5: Adjusted for age, gender, HbA1c, use of medications and comorbidities. Model 6: Adjusted for age, gender, HbA1c, use of medications, comorbidities and HDL.